The short version of certificate of analysis fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-21. Anything still debated is marked as such rather than presented as settled.
Other methods address specific purity concerns. Amino acid analysis gives compositional data after hydrolysis, while capillary electrophoresis separates by charge-to-mass ratio. Karl Fischer titration measures residual water, and gas chromatography can detect residual solvents. Nuclear magnetic resonance can identify organic impurities but is less sensitive for trace levels. No single test covers all possible impurities, so purity testing usually combines orthogonal methods and reports the conditions used. The choice of methods is guided by the impurity classes of interest.
Reverse-phase high-performance liquid chromatography (RP-HPLC) is widely used to estimate peptide purity. It separates components by hydrophobicity on a column with a water-organic mobile phase. Ultraviolet absorbance at 214 nm or 220 nm detects peptide bonds. The main peak area as a percentage of total peak area gives a purity figure. This figure depends on column, gradient, wavelength, and how peaks are integrated, so it is method-specific rather than absolute.
Quality control relies on predefined specifications rather than a single purity number. A certificate of analysis typically lists the test method, acceptance limit, and measured result for each attribute. Common specifications include appearance, peptide content, water content, counterion identity, and related substances. Limits are set according to the peptide's intended use and the capability of the analytical method. A result outside a limit triggers investigation, not automatic rejection, because method variability and sample handling can affect outcomes.
Sample handling influences measured purity. Lyophilized peptides are hygroscopic and can absorb water, changing weight-based calculations, while repeated freeze-thaw cycles may promote aggregation or degradation. Dissolved samples should be prepared fresh when possible and protected from light and heat. In purity testing, the same handling conditions should apply to standards and samples. Stability-indicating methods are designed to separate degradation products from the parent peptide, though open questions remain about how accelerated stability data predict long-term behavior for every sequence.
| Property | Value | Notes |
|---|---|---|
| Typical analytical method | RP-HPLC with UV detection | Separates by hydrophobicity; purity is method-dependent |
| Confirmatory method | LC-MS or MALDI-TOF MS | Provides molecular mass and impurity mass information |
| Common detection wavelength | 214 nm or 220 nm | Peptide bond absorbance; also 280 nm for aromatic residues |
| Typical purity specification | 95% or greater by HPLC area | Common research grade; exact threshold depends on application |
| Sample preparation | Dissolve in water/acetonitrile with acid | Formic acid or trifluoroacetic acid often used |
Reversed-phase high-performance liquid chromatography (RP-HPLC) is widely used to estimate peptide purity. Separation depends on interactions between peptide residues and a hydrophobic stationary phase, with gradients of water and organic solvent. Ultraviolet detection near 214 nm responds to the peptide backbone and to many related impurities. The resulting chromatogram is often expressed as area percent, which reports the proportion of peak area assigned to the main component. Different columns, gradients, and wavelengths can produce different purity values for the same material.
Mass spectrometry provides complementary information about molecular identity and certain impurities. Electrospray ionization and matrix-assisted laser desorption/ionization are common ionization techniques for peptides. A measured mass close to the expected value supports correct sequence length and modifications, while extra mass signals can reveal truncations, adducts, or incomplete deprotection. Mass spectrometry alone is not a quantitative purity assay, because ionization efficiency varies between compounds. Coupling liquid chromatography to mass spectrometry links retention time with mass and helps assign peaks that ultraviolet detection records.
Quality control for peptide products relies on written procedures, batch records, and certificates of analysis. A certificate of analysis typically lists the test methods, specifications, and results for a specific lot. Batch records document synthesis, purification, and testing steps so that results can be traced to process conditions. Method validation establishes accuracy, precision, specificity, linearity, and limits of detection. These records support consistency across lots and allow laboratories to investigate deviations when a specification is not met.
Storage conditions influence purity and therefore testing outcomes. Lyophilized peptides are generally kept cool and dry, while solutions may require refrigeration or freezing depending on sequence and buffer. Repeated freeze-thaw cycles can promote aggregation, oxidation, or hydrolysis. Testing after storage should use the same validated method as release testing to allow comparison. Stability studies examine how purity changes over time under defined temperature and humidity conditions. Results are compared against baseline data collected at release.
Regulatory frameworks treat peptide purity as part of product quality, though requirements vary by intended use and jurisdiction. Investigational materials may need identity, strength, quality, and purity documentation. Compendial monographs, when available, specify tests and acceptance criteria for certain peptides. For research peptides, oversight is often less prescriptive, and buyers may rely on supplier documentation. Open questions remain about how to standardize impurity reporting across laboratories and how to define purity for complex or modified peptides.
Peptide purity specifications describe the minimum acceptable result from a defined test. A certificate of analysis may list HPLC purity, mass spectrometry identity, appearance, and counterion content. Specifications are method-dependent, so a value obtained with one gradient or wavelength may differ from another. For research use, common thresholds include 95% and 98% by RP-HPLC, but the appropriate limit depends on the application. The specification should always name the analytical method and acceptance criterion.
Quality control includes system suitability, blank injections, and reference standards. System suitability checks column performance and retention time reproducibility, while blank runs detect carryover or mobile-phase contaminants. Reference standards help calibrate retention time and detector response. Without these controls, a purity value is difficult to compare across laboratories or over time. Documentation of instrument settings and integration parameters is also part of quality control, and acceptance criteria should be set before samples are analyzed.
Quality control specifications for peptides typically include appearance, identity, purity by RP-HPLC, water content, counterion content, and residual trifluoroacetic acid. Karl Fischer titration measures water, while ion chromatography or elemental analysis can quantify counterions. Purity specifications may be set at 95% or 98% area percent, but the appropriate threshold depends on the application. For research reagents, a lower purity may be acceptable if identity is confirmed. For assays sensitive to impurities, higher purity and orthogonal testing are often required.
Handling and storage influence measured purity, and peptides can oxidize, deamidate, aggregate, or adsorb to surfaces over time. Lyophilized powders stored at -20 °C or lower are generally more stable than solutions, though some sequences require different conditions. Repeated freeze-thaw cycles can promote aggregation and loss, so testing after storage checks whether purity has changed. Stability-indicating methods compare stressed and unstressed samples to detect degradation pathways. Light exposure and pH can also accelerate modification.
=== Cancer therapy === Experimental studies indicate that macrophages can affect all therapeutic modalities, including surgery, chemotherapy, radiotherapy, immunotherapy and targeted therapy. Macrophages can influence treatment outcomes both positively and negatively. Macrophages can be protective in different ways: they can remove dead tumor cells (in a process called phagocytosis) following treatments that kill these cells; they can serve as drug depots for some anticancer drugs; they can also be activated by some therapies to promote antitumor immunity. Macrophages can also be deleterious in several ways: for example they can suppress various chemotherapies, radiotherapies and immunotherapies. Because macrophages can regulate tumor progression, therapeutic strategies to reduce the number of these cells, or to manipulate their phenotypes, are currently being tested in cancer patients. However, macrophages are also involved in antibody mediated cytotoxicity (ADCC) and this mechanism has been proposed to be important for certain cancer immunotherapy antibodies. Similarly, studies identified macrophages genetically engineered to express chimeric antigen receptors as promising therapeutic approach to lowering tumor burden.
=== Traditional inhibitors === Traditionally, there were two major corrosion inhibitors used in vehicles: silicates and phosphates. American-made vehicles traditionally used both silicates and phosphates. European makes contain silicates and other inhibitors, but no phosphates. Japanese makes traditionally use phosphates and other inhibitors, but no silicates.
Bogert (1890), former president of the American Chemical Society and the Society of Chemical Industry William King Gregory (1900), zoologist, primatologist, paleontologist Reuben Ottenberg (1902), physician and haematologist Clinton Gilbert Abbott (1903), ornithologist, naturalist, director of the San Diego Natural History Museum Irving Langmuir (1903), winner of the 1932 Nobel Prize in Chemistry Edward Calvin Kendall (1906), winner of the 1950 Nobel Prize in Physiology or Medicine Harold E. B. Pardee (1906), pioneer in electrocardiogram research, namesake of Pardee's sign Grover Loening (1908), aircraft manufacturer, founder of Loening Aeronautical Engineering; developed the Loening Model 23, which won the 1921 Collier Trophy Michael Heidelberger (1909), immunologist, "father of modern immunology" Ernst Philip Boas (1910), physician and professor at Columbia University College of Physicians and Surgeons, son of German-American anthropologist Franz Boas Hermann Joseph Muller (1910), geneticist and winner of the Nobel Prize in Physiology or Medicine Ralph Randles Stewart (1911), botanist and founder of the National Herbarium, Islamabad Ludlow Griscom (1912), pioneer in field ornithology John Howard Northrop (1912), winner of the 1946 Nobel Prize in Chemistry Calvin Bridges (1912), geneticist, protege of Thomas Hunt Morgan known for his contribution to genetics Irving H.
== Mythological origins == In Greek mythology, the centaur Chiron was a "Wounded Healer", after being poisoned with an incurable wound by one of Hercules's arrows. Jung mentioned the Chiron myth "wounding by one's own arrow means, first of all, the state of introversion"; For Jung, "a good half of every treatment that probes at all deeply consists in the doctor's examining himself... it is his own hurt that gives a measure of his power to heal. This, and nothing else, is the meaning of the Greek myth of the wounded physician." Jung felt that depth psychology can be potentially dangerous, because the analyst is vulnerable to being infected by his analysis by having his own wounds reopened. To avoid this, the analyst must have an ongoing relationship with the unconscious, otherwise he or she could identify with the "healer archetype", and create an inflated ego. Withdrawal of both projections may however ultimately activate the powers of the inner healer in the patients themselves. Jung’s closest colleague, Marie Louise Von Franz, said “the wounded healer IS the archetype of the Self [our wholeness, the God within] and is at the bottom of all genuine healing procedures.” Jungians warn of the dangers of inflation and splitting in the helping professions, involving projection of the 'wounded' pole of the archetype onto the patient alone, with the analyst safely separated off as 'healer'.
Sources: en.wikipedia.org
== See also == Air-free technique – Chemistry laboratory technique Acidic oxide – Type of oxide, a.k.a. acid anhydride Base anhydride – Oxide of a chemical element from alkali- or alkaline earth metals Hydrate – Substance containing water or its constituent elements
==== 1952–53 ==== When he joined the Cardinals, broadcaster Harry Caray started calling him "Vinegar Bend," and the nickname stuck. He was hailed as "the left-handed Dizzy Dean" by sportswriter Red Smith, which Mizell called "a perty heavy load for a boy to tote." Added to St. Louis's starting rotation for the 1952 campaign, Mizell made his major league debut on April 22 against the Cincinnati Reds. He gave up two runs in the first inning, then held the Reds scoreless for the rest of the game, though he took the loss in a 2–1 defeat. Two starts later, on May 2, he limited the Philadelphia Phillies to four hits and two runs in a complete game, winning in the ninth when Peanuts Lowrey broke a 2–2 tie with an RBI-single. After that win, he lost three games in a row, then received four consecutive no decisions. He ended the winless streak on June 21, when he struck out 11 in his first major league shutout against the Boston Braves. That started a streak of six decisions won in a row, during which time Mizell posted a 3.05 ERA. He would not lose again until August 27. On September 5, he threw his second shutout of the year, tying his season high with 11 strikeouts in a 4–0 victory over the Pittsburgh Pirates. Mizell finished his rookie season with a 10–8 record and a 3.65 ERA in 30 starts. He led the National League (NL) in strikeouts per 9 innings pitched with a 6.9 mark, and his 146 strikeouts ranked fourth in the league (behind Warren Spahn's 183, Bob Rush's 157, and Robin Roberts's 148). However, he also led the league in walks (103, tied with Herm Wehmeier).
Money, or its hectic pursuit, has been shown to hinder people's savoring ability, or the act of enjoying everyday positive experiences and emotions. In a study looking at working adults, wealthy individuals reported lower levels of savoring ability (the ability to prolong positive emotion) relative to their poorer peers. Studies have routinely shown that nations are happier when people's needs are met. Some studies suggest, however, that people are happier after spending money on experiences, rather than physical things, and after spending money on others, rather than themselves. However, purchases that buy 'time', for instance, cleaners or cooks typically increase individual well-being. Lottery winners report higher levels of happiness immediately following the event. But research shows winner's happiness levels drop and return to normal baseline rates within months to years. This finding suggests money does not cause long-term happiness (1978). However, in a more recent British study on lottery prizes between £1,000 and £120,000, a positive effect even two years after the event was found, the return to normal being only partial and varying. One 600 women strong 2011 study shows that house owners are no happier than renters. Degree of ownership also matter: "...housing property rights matter for subjective well-being.
Sources: en.wikipedia.org
It usually refers to the relative area of the main peak in a chromatographic separation, such as RP-HPLC. It estimates the proportion of UV-absorbing material in that peak, not the absolute mass fraction of the target peptide. Different methods can give different percentages.
HPLC separates and quantifies components, while mass spectrometry identifies molecular masses. Together they can show whether a main peak has the expected mass and whether other peaks correspond to related peptide variants. This combination is more informative than either method alone.
Higher purity reduces the proportion of detectable related impurities, which can matter for research reproducibility. However, purity value alone does not establish identity, biological activity, or safety. The appropriate purity depends on the intended use and the sensitivity of the assay.
A related substance is a peptide-like impurity that resembles the target sequence, such as a truncated or modified form. It is often reported as individual and total area percent.